Positron-emission tomography (PET) scans and radioligands specific for the 18-kDa TSPO, a mitochondrial protein that is upregulated in activated glial cells, provide a useful index for measuring neuroinflammation in living patients. {read more here}

Patients with suspected dementia that remains unclarified after PET imaging with the standard radiotracer fluordeoxyglucose (FDG) should be sent for amyloid-busting PET with florbetaben (FBB), as the latter is highly useful in establishing a final diagnosis in such situations. {read more here}

Imaging agents for the detection of biochemical recurrent prostate cancer could move beyond computed tomography (CT) and magnetic resonance imaging (MRI) in the near future, with the emergence of prostate-specific membrane antigen (PSMA)-PET, particularly in oligometastatic disease, with a high-detection sensitivity rate, explains Thomas Hope, MD. {read more here}

CCL11 could eventually be used in combination with other biomarkers and procedures, such as positron emission tomography, or PET scans, to diagnose CTE in the living, according to the study.  {read more here}